Aprea Therapeutics Announces Abstract Featuring Updated Interim Results From The Ongoing Phase 1 ACESOT-1051 Study Of Its WEE1 Inhibitor APR-1051 In Patients With Advanced Solid Tumors Has Been Accepted For Oral Presentation At The Symposium On... — Dernières actualités